Amgen (AMGN) Income towards Parent Company (2009 - 2026)
Amgen (AMGN) posted Income towards Parent Company of $2.4 billion for Q2 2026, up 30.57% on a QoQ basis from $1.8 billion in Q1 2026, and up 65.85% year-over-year from $1.4 billion in Q2 2025.
Analysis
Amgen (AMGN) Income towards Parent Company (2009 - 2026) Analysis & Trends
Amgen has reported Income towards Parent Company for 18 years, with the latest figure at $2.4 billion in Q2 2026.
- On a quarterly basis, Income towards Parent Company rose 65.85% year-over-year to $2.4 billion in Q2 2026; TTM through Jun 2026 was $8.7 billion, a 32.09% increase from a year earlier, with the FY2025 full-year figure at $7.7 billion, up 88.53% from the prior year.
- Income towards Parent Company was $2.4 billion for Q2 2026 at Amgen, up from $1.8 billion in the prior quarter.
- The five-year high for Income towards Parent Company was $3.2 billion in Q3 2025, with the low at -$113.0 million in Q1 2024.
- Average Income towards Parent Company over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2022.
- The sharpest annual moves came in 2024 and 2025: Income towards Parent Company tumbled 103.98% in 2024, then soared 1630.97% in 2025.
- Over 5 years, Income towards Parent Company stood at $1.6 billion in 2022, then sank by 52.54% to $767.0 million in 2023, then decreased by 18.25% to $627.0 million in 2024, then jumped by 112.6% to $1.3 billion in 2025, then surged by 78.17% to $2.4 billion in 2026.
- The last three Income towards Parent Company figures came in at $2.4 billion (Q2 2026), $1.8 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn |
| 10 | Insmed | 26.19 Bn | 25.03 Bn | 358.27 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.38 Bn |
| Mar 31, 2026 | 1.82 Bn |
| Dec 31, 2025 | 1.33 Bn |
| Sep 30, 2025 | 3.22 Bn |
| Jun 30, 2025 | 1.43 Bn |
| Mar 31, 2025 | 1.73 Bn |
| Dec 31, 2024 | 627.00 Mn |
| Sep 30, 2024 | 2.83 Bn |
| Jun 30, 2024 | 746.00 Mn |
| Mar 31, 2024 | -113.00 Mn |
| Dec 31, 2023 | 767.00 Mn |
| Sep 30, 2023 | 1.73 Bn |
| Jun 30, 2023 | 1.38 Bn |
| Mar 31, 2023 | 2.84 Bn |
| Dec 31, 2022 | 1.62 Bn |
| Sep 30, 2022 | 2.14 Bn |
| Jun 30, 2022 | 1.32 Bn |
| Mar 31, 2022 | 1.48 Bn |
| Dec 31, 2021 | 1.90 Bn |
| Sep 30, 2021 | 1.88 Bn |